Systematic review of factors affecting pharmaceutical expenditures

Health Policy

Volumn 116, Issue 2-3, 2014, Pages 137-146

  Mousnad, Mohamed Awad ^a   Shafie, Asrul Akmal ^b   Ibrahim, Mohamed Izham ^c  

^a National Health Insurance Fund   (Sudan)

^b SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^c College of Pharmacy Qatar University ^*  (Qatar)

Author keywords

Drug financing; Drug quantities changes; Drug therapies changes; New drugs; Pharmaceutical expenditures; Spending determinants

Indexed keywords

COMPARATIVE EFFECTIVENESS; DRUG COST; DRUG QUALITY; DRUG USE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROMOTION; HEALTH SERVICE; HUMAN; PHARMACEUTICAL CARE; PHARMACY; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; DRUG THERAPY; ECONOMICS; HEALTH CARE DELIVERY; ORGANIZATION AND MANAGEMENT; STATISTICS AND NUMERICAL DATA; UTILIZATION;

DRUG;

DELIVERY OF HEALTH CARE; DRUG COSTS; DRUG THERAPY; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84900803895     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2014.03.010     Document Type: Review

References (75)

1. Thomas R. Health services demand and utilization. Health Services Planning 2003, 55-73. Springer US.
2. Annan K.A. We the peoples: the role of the United Nations in the 21st century 2000, United Nations.
3. Smith R.D., Correa C., Oh C. Trade, TRIPS, and pharmaceuticals. The Lancet 2009, 373(9664):684-691.
4. Ess S.M., Schneeweiss S., Szucs T.D. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003, 21(2):89-103.
5. Morgan S.G. The determinants of prescription drug expenditure and what to do about them April 2008, UBC Centre for Health Services and Policy Research, Available from: http://www.chspr.ubc.ca/ [cited 2.06.10].
6. de Joncheere K. The role of the World Health Organization on pharmaceuticals in Europe. Value in Health 2001, 4(3):217-224.
7. Merlis M. Explaining the growth in prescription drug spending: a review of recent studies 2000, Available from: http://aspe.hhs.gov/health/reports/drug-papers/merlis/merlis-final.htm.
8. Noyce P.R., Huttin C., Atella V., Brenner G., Haaijer-Ruskamp F.M., Hedvall M-B., et al. The cost of prescription medicines to patients. Health Policy 2000, 52(2):129-145.
9. Armstrong R., Waters E., Jackson N., Oliver S., Popay J., Shepherd J., et al. Guidelines for Systematic reviews of health promotion and public health interventions 2007, Available from: www.vichealth.vic.gov.au/cochrane [cited 06.06.10].
10. EPHPP The Effective Public Health Practice Project. The quality assessment tool for quantitative studies 2010, Available from: http://www.city.hamilton.on.ca/phcs/EPHPP/ [cited 06.06.10].
11. Petticrew M., Roberts H. MyiLibrary. Systematic reviews in the social sciences: a practical guide 2006, Blackwell Pub., Oxford.
12. Centre for Reviews and Dissemination. Systematic Reviews. CRD's guidance for undertaking reviews in health care. York; 2009. Available from:. http://www.york.ac.uk/inst/crd/systematic_reviews_book.htm.
13. Anderson G., Kerluke K. Distribution of prescription drug exposures in the elderly: description and implications. Journal of Clinical Epidemiology 1996, 49(8):929-935.
14. Cavalié P. Is therapeutic innovation responsible for the increase in drug expenditure?. The European Journal of Health Economics 2003, 4(3):184-194.
15. Chernew M.E., Smith D.G., Kirking D.M., Fendrick A.M. Decomposing pharmaceutical cost growth in different types of health plans. The American Journal of Managed Care 2001, 7(7):667.
16. Darbà J. Pharmaceutical expenditure in Spain: evolution and cost containment measures during 1998-2001. The European Journal of Health Economics 2003, 4(3):151-157.
17. Dubois R.W., Chawla A.J., Neslusan C.A., Smith M.W., Wade S. Explaining drug spending trends: does perception match reality?. Health Affairs 2000, 19(2):231-239.
18. Gerdtham U.G., Johannesson M., Gunnarsson B., Marcusson M., Henriksson F. The effect of changes in treatment patterns on drug expenditure. Pharmacoeconomics 1998, 13(1 Pt. 2):127-134.
19. Gerdtham U-G., Lundin D. Why did drug spending increase during the 1990?: a decomposition based on Swedish data. Pharmacoeconomics 2004, 22(1):29-42.
20. Hanley G.E., Morgan S. Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada. Social Science & Medicine 2009, 68(5):919-924.
21. Hoffman J.M., Doloresco F., Vermeulen L.C., Shah N.D., Matusiak L., Hunkler R.J., et al. Projecting future drug expenditures-2010. American Journal of Health-System Pharmacy 2010, 67:919-928.
22. Hoffman J.M., Shah N.D., Vermeulen L.C., Doloresco F., Grim P., Hunkler R.J., et al. Projecting future drug expenditures-2008. American Journal of Health-System Pharmacy 2008, 65(3):234-253.
23. Hsieh C.-R., Sloan F.A. Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective?. Value in Health 2008, 11(2):334-344.
24. Kildemoes H.W., Andersen M., Støvring H. The impact of ageing and changing utilization patterns on future cardiovascular drug expenditure: a pharmacoepidemiological projection approach. Pharmacoepidemiology and Drug Safety 2010, 19(12):1276-1286.
25. Lambrelli D., Donnell O. The impotence of price controls: failed attempts to constrain pharmaceutical expenditures in Greece. Health Policy 2010, 101(2):162-171.
26. Morgan S.G. Quantifying components of drug expenditure inflation: the British Columbia seniors' drug benefit plan. Health Services Research 2002, 37(5):1243-1266.
27. Morgan S.G., Agnew J.D., Barer M.L. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia. Health Policy 2004, 68(3):299-307.
28. Morgan S. Drug spending in Canada: recent trends and causes. Materials Characterization 2004, 42(7):635-642.
29. Morgan S.G. Booming prescription drug expenditure: a population-based analysis of age dynamics. Medical Care 2005, 99:6-1008.
30. Morgan S.G. Prescription drug expenditures and population demographics. Health Services Research 2006, 41(2):411-428.
31. Mueller C., Schur C., O'Connell J. Prescription drug spending: the impact of age and chronic disease status. Australian Journal of Public Health 1997, 87(10):1626-1629.
32. Mullins C.D., Wang J., Palumbo F.B., Stuart B. The impact of pipeline drugs on drug spending growth. Health Affairs 2001, 20(5):210-215.
33. Sherman D. Factors affecting the growth of prescription drug expenditures 1999, The National Institute for Health Care Management Research and Educational Foundation, Washington, DC, Available from: www.nihcm.org/mainframe.html [cited 15.04.09].
34. Steinberg E.P., Gutierrez B., Momani A., Boscarino J.A., Neuman P., Deverka P. Beyond survey data: a claims-based analysis of drug use and spending by the elderly. Health Affairs 2000, 19(2):198-211.
35. Suh D.-C., Lacy C.R., Barone J.A., Moylan D., Kostis J.B. Factors contributing to trends in prescription drug expenditures. Clinical Therapeutics 1999, 21(7):1241-1253.
36. Van Tielen R., Peys F., Genaert J. The demographic impact on ambulatory pharmaceutical expenditure in Belgium. Health Policy 1998, 45(1):1-14.
37. Vandegrift D., Datta A. Prescription drug expenditures in the united states: the effects of obesity, demographics, and new pharmaceutical products. Southern Economic Journal 2006, 73(2):515-529.
38. Higgins J. Green Se Cochrane handbook for systematic reviews of interventions 2009, The Cochrane Collaboration, Available from: www.cochrane-handbook.org [cited 06.04.10].
39. Andersson F. Methodological aspects of international drug price comparisons. Pharmacoeconomics 1993, 4(4):247.
40. Mossialos E., Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. The International Journal of Health Planning and Management 2005, 20(4):291-306.
41. Humpage O.F. Rising relative prices or inflation: why knowing the difference matters. Economic Commentary 2008, (June).
42. Rovira J., Tremosa R., Gilabert A., Torralba M. The role of prices in drug expenditure analysis. The European Journal of Health Economics 2001, 2(4):142-149.
43. Diewert W.E. Index numbers. The new Palgrave dictionary of economics 1987, Macmillan Reference USA, New York. J.M.M. Eatwell, P. Newman (Eds.).
44. Thomas J., Schondelmeyer S. Price indexes for pharmaceuticals used by the elderly. Health Care Financing Review 1992, 14(1):91.
45. Danzon P.M., Kim J.D. International price comparisons for pharmaceuticals: measurement and policy issues. Pharmacoeconomics 1998, 14:115-128.
46. Jönsson B. Cost sharing for pharmaceuticals-the Swedish reimbursement system. Pharmacoeconomics 1996, 10(Suppl. 2):68-74.
47. Gerdtham U.-G., Johannesson M., Jönsson B. Drug expenditure and new drug introductions: the Swedish experience. Pharmacoeconomics 1993, 4(3):215-225.
48. Gerdtham U.G., Johannesson M., Gunnarsson B., Marcusson M., Henriksson F. Price indices of drugs and the switching to new drugs: two empirical examples. Pharmacoeconomics 1998, 13(1 Part 2):71-80.
49. Burstall M.L. The management of the cost and utilisation of pharmaceuticals in the United Kingdom. Health Policy 1997, 41(Suppl.):S27-S43.
50. Ljungkvist M.O., Andersson D., Gunnarsson B. Cost and utilisation of pharmaceuticals in Sweden. Health Policy 1997, 41:S55-S69.
51. Teitelbaum F., Roe C.M., Fendrick A.M. Pharmacy management trends: a guide for new physicians. Seminars in Medical Practice 2000, 3(1):22-31.
52. Berndt E.R. Health Affairs 2001, 20(2):100-114.
53. Vogel R.J. The reasons behind increasing pharmaceutical expenditures. A technical paper 2002, 1-12. Available from: http://boulderblast.com/publications/studies _research/pdfs/CoA_Pharmaceutical_Expenditures.pd [29.06.10].
54. FDA Generic drugs: questions and answers 2010, Food and Drug Administration, USA, Available from: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm100100.htm [cited 12.11.11].
55. Allan G.M., Lexchin J., Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Medicine 2007, 4(9):e283. 10.1371/journal.pmed.0040283.
56. Zhang Y., Donohue J.M., Lave J.R., O'Donnell G., Newhouse J.P. The effect of Medicare Part D on drug and medical spending. New England Journal of Medicine 2009, 361(1):52-61.
57. Fu A.Z., Tang A.S., Wang N., Du D.T., Jiang J.Z. Effect of Medicare Part D on potentially inappropriate medication use by older adults. Journal of the American Geriatrics Society 2010, 58(5):944-949.
58. Millett C., Everett C.J., Matheson E.M., Bindman A.B., Mainous A.G. Impact of Medicare Part D on seniors' out-of-pocket expenditures on medications. Archives of Internal Medicine 2010, 170(15):1325.
59. Lopez-Casasnovas G., Puig-Junoy J. Review of the literature on reference pricing. Health Policy 2000, 54(2):87-123.
60. Dukes M.N.G. Drugs and money: prices, affordability and cost containment 2003, 15. IOS Press, Copenhagen, Available from: http://www.euro.who.int/__data/assets/pdf_file/0011/96446/e79122.pdf [cited 10.05.10].
61. Soumerai S.B., Ross-Degnan D., Gortmaker S., Avorn J. Withdrawing payment for nonscientific drug therapy. The Journal of the American Medical Association 1990, 263(6):831.
62. Dickson M., Redwood H. Pharmaceutical reference prices: how do they work in practice?. Pharmacoeconomics 1998, 14(5):471-479.
63. Ioannides-Demos L.L., Ibrahim J.E., McNeil J.J. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics 2002, 20(9):577-591.
64. Rietveld A.H., Haaijer-Ruskamp F.M. Policy options for cost containment of pharmaceuticals. Drugs and money 2003, 29-54. Published on behalf of the World Health Organization Regional Office for Europe by IOS Press, Copenhagen. M.N.G.H.-R. Dukes, F.M. de Joncheere, C.P.A.H. Rietveld (Eds.).
65. Simoens S. International comparison of generic medicine prices. Current Medical Research and Opinion 2007, 23(11):2647-2654.
66. Sebastian S. Reference drug programs: effectiveness and policy implications. Health Policy 2007, 81(1):17-28.
67. Kanavos P., Reinhardt U. Reference pricing for drugs: is it compatible with U.S. Health Care?. Health Affairs 2003, 22(3):16-30.
68. Giuliani G., Selke G., Garattini L. The German experience in reference pricing. Health Policy 1998, 44(1):73-85.
69. Aaserud M., Dahlgren A., Kösters J., Oxman A., Ramsay C., Sturm H. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database of Systematic Reviews [Internet] 2006, (2). [Art. No.: CD005979]. Available from: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005979/frame.html [10.05.10]. 10.1002/14651858.CD005979.
70. Mrazek M.F. Comparative approaches to pharmaceutical price regulation in the European Union. Croatian Medical Journal 2002, 43(4):453-461.
71. Yang B.-M. The future of health technology assessment in healthcare decision making in Asia. Pharmacoeconomics 2009, 27(11):891-901.
72. Hochman M., McCormick D. Characteristics of published comparative effectiveness studies of medications. The Journal of the American Medical Association 2010, 303(10):951-958.
73. Perlroth D.J., Goldman D.P., Garber A.M. The potential impact of comparative effectiveness research on US health care expenditures. Demography 2010, 47(1):S173-S190.
74. Basu A., Jena A.B., Philipson T.J. The impact of comparative effectiveness research on health and health care spending. Journal of Health Economics 2011, 30(4):695-706.
75. Armstrong D.J. Reviews in health promotion and public health. Cochrane handbook for systematic reviews of interventions 2008, John Wiley & Sons, Chichester, UK. H.J. Gse (Ed.).